SCHEMBL21361650

SCHEMBL21361650

O=S(=O)(N1CCCCC1)N1CCCNCCCN(S(=O)(=O)N2CCCCC2)CC2(CC2)C1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.60
POLB P06746 1/20 0.48
TSHR P16473 5/20 0.47
KMT2A Q03164 3/20 0.47
ALDH1A1 P00352 7/20 0.38
MEN1 O00255 2/20 0.38
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.33
USP2 O75604 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
HSD17B10 Q99714 1/20 0.33
HIF1A Q16665 1/20 0.33
HTR2C P28335 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3176249 0.76 KDM4E (1.00) KDM4EPOLBTSHRKMT2AALDH1A1
SCHEMBL16439724 0.74 KDM4E (0.95) KDM4EPOLBTSHRKMT2AALDH1A1
SCHEMBL29905605 0.71 POLB (0.93) KDM4EPOLBTSHRKMT2AALDH1A1
SCHEMBL5280013 0.71 POLB (0.93) KDM4EPOLBTSHRKMT2AALDH1A1
SCHEMBL1546827 0.68 POLB (0.87) KDM4EPOLBTSHRKMT2AALDH1A1
SCHEMBL17047362 0.68 POLB (0.54) KDM4EPOLBTSHRKMT2AALDH1A1
SCHEMBL7423339 0.66 KDM4E (0.80) KDM4EPOLBTSHRKMT2AALDH1A1
Piperidine SCHEMBL6170163 0.66 CA2 (0.71) KDM4EPOLBTSHRKMT2AALDH1A1
Hydrochloric Acid SCHEMBL6766618 0.66 TSHR (0.62) KDM4EPOLBTSHRKMT2AALDH1A1
SCHEMBL9028142 0.63 POLB (0.67) KDM4EPOLBTSHRKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-12-22 US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 US disclosed
WO-2019178510-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2019-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G KDM4E 4672/4885POLB 3315/4885TSHR 727/4885
US-20220402891-A1 TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G KDM4E 4689/4885POLB 3166/4885TSHR 976/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G KDM4E 4717/4885POLB 3175/4885TSHR 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.